Heart-Chip Review Examines Maturation, Functional Readouts and Drug Diversity
A Micromachines review surveys heart-on-a-chip fabrication, stimulation and sensing. Its pharmacological examples connect tissue conditioning with electrical and contractile drug responses, while exposing limits in reference-drug coverage and reproducibility.
The Assay Depends on the Tissue and the Measurement
A review from George Fox University surveys recent heart-on-a-chip research, from device fabrication and tissue conditioning to disease models and drug testing. It treats engineered cardiac function as the result of interacting choices: cell source, architecture, mechanical loading, electrical pacing and the method used to record a response.
The drug-testing question changes with those choices. A system designed to measure force may reveal contractile suppression, while an electrode-based preparation may be more informative about repolarization or conduction. Combined measurements can connect these functions, but a beating tissue or a cardiac marker alone provides limited evidence about the range of pharmacological effects an assay can detect.
The source is a narrative review of heterogeneous studies. It does not report a new comparative drug panel or pooled accuracy estimate. Its examples include human stem-cell-derived tissues and animal-cell preparations, whose origins remain relevant when comparing their results.
Fabrication and Conditioning Set the Baseline
Soft lithography, printing, hot embossing and related fabrication methods provide different levels of geometric control and manufacturing complexity. Polydimethylsiloxane, or PDMS, supports flexible structures and rapid prototyping, but drug–material interactions can alter effective exposure. Thermoplastic and printed devices offer alternatives with their own constraints in resolution, bonding and integration.
The review describes mechanical loading through diaphragms, flexible posts, patterned substrates and tissue tension. One cited human cardiac system applied 10% uniaxial strain at 1 Hz and recorded electrical activity from three-dimensional microtissues. In a separate fibroblast-focused preparation, physiological-range and higher pathological-range strains produced different activation responses. Thus, loading can modify the disease phenotype as well as tissue maturation.
Electrical pacing can synchronize contraction and promote selected structural or functional features. Flexible-wire systems also convert tissue-driven deflection into a force estimate. Some platforms combine mechanical and electrical stimulation, increasing the number of controlled inputs and the burden of maintaining them reproducibly. Culture duration, stimulus strength and the resulting baseline behavior influence the subsequent drug comparison.
Drug Examples Span Electrical and Mechanical Effects
The mechanically trained microtissue example showed a corrected field-potential-duration increase of up to about 80% with sotalol and a reduction of up to about 40% with verapamil. These are reported electrical responses within that preparation. Their interpretation depends on the acquisition method, rate correction and model baseline.
The review also describes a printed platform tested with nifedipine and lidocaine. The reported responses included suppression of contraction and calcium-transient measures. These readouts connect a drug’s effect on excitation or calcium handling with the mechanical output of the tissue, rather than treating viability as the sole endpoint.
A linked heart–breast-cancer chip provides another use case. Doxorubicin reduced tumor growth and cancer-cell viability while also lowering cardiac contractile function and beating amplitude. The cited work reported less cardiotoxicity with a nanoparticle formulation than with the free drug. That comparison concerns a specific formulation and linked-tissue experiment; it does not establish a general safety advantage for nanoparticle delivery.
Multiorgan designs add further exposure steps. The review discusses a skin–liver–heart system in which a barrier controls entry and liver tissue encounters the compound before cardiac tissue. Such configurations can investigate how administration and metabolism change the cardiac response, provided transport and tissue function are characterized together.
Disease Models Change Which Endpoint Matters
The surveyed disease applications include ischemic stress, inherited cardiomyopathy and regional fibrosis. Hypoxia and glucose deprivation in human induced-pluripotent-stem-cell-derived cardiomyocytes impaired contraction and produced arrhythmic behavior; the review describes a levosimendan intervention that reduced ischemia-associated arrhythmias. Patient-derived Barth-syndrome tissues supplied a different comparison involving mitochondrial abnormalities, sarcomere organization and weak contraction.
A spatially patterned fibrosis chip organized healthy, border and scar regions and added immune cells through a controlled-delivery structure. That design offers a way to study regional cell interactions, with reproducible patterning becoming an important manufacturing challenge. The review notes that a focus on one immune population can leave other inflammatory or endothelial interactions unrepresented.
Vascularization can improve transport and cell communication, but vessel formation and maintenance need to coexist with the requirements of cardiomyocytes. An endothelial channel does not necessarily recreate capillaries throughout the myocardial compartment. Likewise, an apparently mature tissue shape may still differ from ventricular architecture or adult electromechanical performance.
A Narrow Reference Panel Leaves Unanswered Questions
Several platforms in the review were evaluated with only one or two reference drugs. A verapamil-only experiment tests a limited pharmacological response, while isoproterenol and nifedipine emphasize rate or calcium-related effects. Oxidative injury, sodium-channel-dependent conduction changes and other mechanisms require additional challenges. The authors discuss doxorubicin and flecainide as examples that broaden this coverage.
Immature stem-cell-derived cardiomyocytes, variation among lines, low force output and differences in stimulation can complicate comparisons. Some sensor designs also underestimate compressive strain or depend on tissue–sensor coupling that changes during culture. Combining real-time force or electrical recording with imaging and molecular characterization helps identify which part of a response is changing.
The review concludes that reproducibility, cellular diversity and therapeutic diversity remain linked problems. A useful evaluation therefore needs a defined cardiac question, a suitable tissue baseline, an interpretable functional measurement and reference interventions that test the relevant mechanism.